Objective Acuity announces successful pilot study in children with CLN2 Batten disease
Objective Acuity announces successful pilot study in children with CLN2 Batten disease News provided by Share this article AUCKLAND, New Zealand, May 10, 2021 /PRNewswire/ -- Objective Acuity ("OAL") today announced the completion of a pilot study using OAL's threshold visual acuity test for young children diagnosed with late-infantile neuronal ceroid lipofuscinosis Type 2 (CLN2 disease), a form of Batten disease. A prominent feature of CLN2 disease is vision loss, which typically develops when cognitive, motor and language impairments are already present. Measurement of visual acuity of t...